Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 1, 2016, Pages 36-44

  Vecchio, Elizabeth A ^a   Tan, Christina Y R ^a   Gregory, Karen J ^a   Christopoulos, Arthur ^a   White, Paul J ^a   May, Lauren T ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; CYCLIC AMP; INOSITOL PHOSPHATE; LIGAND; PSB603; SULFONAMIDE; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL; CELL PROLIFERATION; CHO CELL LINE; CRICETULUS; DRUG DESIGN; DRUG EFFECTS; HAMSTER; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADENOSINE DEAMINASE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG DESIGN; HUMANS; INOSITOL PHOSPHATES; LIGANDS; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATIC NEOPLASMS; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION; SULFONAMIDES; TRIAZINES; TRIAZOLES; XANTHINES;

EID: 84962520344     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.230003     Document Type: Article

References (46)

1. Barker EL, Westphal RS, Schmidt D, and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
2. 2A receptor define ligand efficacy. Mol Pharmacol 83:949-958.
3. Bond RA and IJzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27:92-96.
4. Borrmann T, Hinz S, Bertarelli DCG, Li W, Florin NC, Scheiff AB, and Müller CE (2009) 1-alkyl-8-(piperazine-1-sulfonyl) phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem 52:3994-4006.
5. Burstein ES, Spalding TA, and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
6. Cárdenas A, Toledo C, Oyarzún C, Sepúlveda A, Quezada C, Guillén-Gómez E, Díaz-Encarnación MM, Pastor-Anglada M, and San Martín R (2013) Adenosine A (2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab Invest 93:135-144.
7. Carmichael J, De Graff WG, Gazdar AF, Minna JD, and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942.
8. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, and Linden J (2012) Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 188:198-205.
9. Chalmers DT and Behan DP (2002) The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov 1:599-608.
10. Eckle T, Kewley EM, Brodsky KS, Tak E, Bonney S, Gobel M, Anderson D, Glover LE, Riegel AK, and Colgan SP, et al. (2014) Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J Immunol 192:1249-1256.
11. Feoktistov I and Biaggioni I (1997) Adenosine A2B receptors. Pharmacol Rev 49:381-402.
12. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, and Linden J (2001a) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
13. Fredholm BB, Irenius E, Kull B, and Schulte G (2001b) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448.
14. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
15. Ham J and Rees DA (2008) The adenosine a2b receptor: its role in inflammation. Endocr Metab Immune Disord Drug Targets 8:244-254.
16. Hopkinson HE, Latif ML, and Hill SJ (2000) Non-competitive antagonism of b (2) - agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active β (2)-adrenoceptors. Br J Pharmacol 131:124-130.
17. Iannone R, Miele L, Maiolino P, Pinto A, and Morello S (2013) Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15:1400-1409.
18. Kasama H, Sakamoto Y, Kasamatsu A, Okamoto A, Koyama T, Minakawa Y, Ogawara K, Yokoe H, Shiiba M, and Tanzawa H, et al. (2015) Adenosine A2b receptor promotes progression of human oral cancer. BMC Cancer 15:563.
19. Kong T, Westerman KA, Faigle M, Eltzschig HK, and Colgan SP (2006) HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20:2242-2250.
20. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
21. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, and Vassart G (1995) Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 332:150-154.
22. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
23. Lefkowitz RJ, Cotecchia S, Samama P, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
24. Li S, Huang S, and Peng S-B (2005) Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 27:1329-1339.
25. Liang BT and Haltiwanger B (1995) Adenosine A2a and A2b receptors in cultured fetal chick heart cells. High- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation. Circ Res 76:242-251.
26. Linden J, Thai T, Figler H, Jin X, and Robeva AS (1999) Characterization of human A (2B) adenosine receptors: radioligand binding, western blotting, and coupling to G (q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 56:705-713.
27. Liu G, Duranteau L, Carel J-C, Monroe J, Doyle DA, and Shenker A (1999) Leydigcell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 341:1731-1736.
28. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 25:402-408.
29. Ma D-F, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, and Katoh R (2010) Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol 41:1550-1557.
30. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
31. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
32. Milligan G and IJzerman AP (2000) Stochastic multidimensional hypercubes and inverse agonism. Trends Pharmacol Sci 21:362-363.
33. Mousavi S, Panjehpour M, Izadpanahi MH, and Aghaei M (2015) Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues. Prostate 75:735-747.
34. Nakahara T, Maruko T, Sakamoto K, and Ishii K (2004) Influence of receptor number on the cAMP response to forskolin in Chinese hamster ovary cells transfected with human beta2-adrenoceptor. Biol Pharm Bull 27:239-241.
35. Neilan CL, Akil H, Woods JH, and Traynor JR (1999) Constitutive activity of the d-opioid receptor expressed in C6 glioma cells: identification of non-peptide d-inverse agonists. Br J Pharmacol 128:556-562.
36. Parra S and Bond RA (2007) Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol 7:146-150.
37. Polosa R and Blackburn MR (2009) Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 30:528-535.
38. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, and Feoktistov I (2008) Host A (2B) adenosine receptors promote carcinoma growth. Neoplasia 10:987-995.
39. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
40. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71-103.
41. Sommerschild HT and Kirkebøen KA (2000) Adenosine and cardioprotection during ischaemia and reperfusion-an overview. Acta Anaesthesiol Scand 44:1038-1055.
42. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
43. Subarsky P and Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20:237-250.
44. Wei Q, Costanzi S, Balasubramanian R, Gao Z-G, and Jacobson KA (2013) A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal 9:271-280.
45. Weyler S, Fülle F, Diekmann M, Schumacher B, Hinz S, Klotz K-N, and Müller CE (2006) Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1, 2, 3-cd] purinediones. ChemMedChem 1:891-902.
46. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Wetsel WC, Mosier PD, Westkaemper RB, Allen JA, and Zjawiony JK, et al. (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the k-opioid receptor. Biochemistry 48:6898-6908.